吉利德科学：市场可能低估其增长潜力（上调评级）(GILD)
· seekingalpha.com
吉利德2026年展望因研发管线加速、Biktarvy和Livdelzi销售额增长而改善，推动业绩指引上调。
Six days ago, on August 4, Gilead Sciences ( GILD ) released its Q2 earnings report. It showed higher sales growth rates for its HIV franchise, Livdelzi, and Tr...